Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
Year: 2026
Type: article
Abstract: Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.
Source: npj Breast Cancer
Institutions: University of Messina, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Universitario 12 De Octubre, Solti, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Barcelona Institute for Global Health, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Universitat de Barcelona, University of Trieste, Azienda Socio Sanitaria Territoriale di Cremona, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliero Universitaria Maggiore della Carita, University of Catania, LMU Klinikum, Ludwig-Maximilians-Universität München, MedSIR (Spain), IDCQ Hospitales y Sanidad, S.L.U., Universidad Europea de Madrid
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,790
Funder: Instituto de Salud Carlos III
Award: G5259577227
OpenAlex ID: W7125979141